NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024
(NYSE MKT:NRXS), CARMEL, Ind., Oct. 29, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Capital Blue Cross Medical Members, effective October […]